32nd EACTS Annual Meeting clinical trials update: ART, IMPAG, MITRA-FR and COAPT

Nick Freemantle; Milan Milojevic; Sern Lim; Stephen Fremes; Domenico Pagano

doi:10.1093/ejcts/ezy396

32nd EACTS Annual Meeting clinical trials update: ART, IMPAG, MITRA-FR and COAPT

Nick Freemantle, Milan Milojevic, Sern Lim, Stephen Fremes, Domenico Pagano

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Original language	English
Pages (from-to)	186-190
Number of pages	5
Journal	European Journal of Cardio-thoracic Surgery
Volume	55
Issue number	2
DOIs	https://doi.org/10.1093/ejcts/ezy396
State	Published - 1 Feb 2019
Externally published	Yes

Access to Document

10.1093/ejcts/ezy396

Cite this

@article{fb4db71609d24eca847fa635f34dddfe,

title = "32nd EACTS Annual Meeting clinical trials update: ART, IMPAG, MITRA-FR and COAPT",

author = "Nick Freemantle and Milan Milojevic and Sern Lim and Stephen Fremes and Domenico Pagano",

note = "Funding Information: a Institute of Clinical Trials and Methodology, University College London, London, UK b Analytical Support Unit, European Association for Cardio-Thoracic Surgery, Windsor, UK c Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands d Department of Cardiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK e Department of Cardiac Surgery, University of Toronto, Toronto, ON, Canada f Department of Cardiothoracic Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK g Secretary General, European Association for Cardio-Thoracic Surgery, Windsor, UK Funding Information: At 1 year, the regulatory standard composite end point of all-cause death or unplanned hospitalization for HF in the device group was similar to the control group (54.6\% vs 51.3\%, odds ratio 1.16, 95\% CI 0.73–1.84; P = 0.53). There was no difference between the device and the control group in the rate of all-cause death (24.3\% vs 22.4\%; HR 1.11, 95\% CI 0.69–1.77), unplanned hospitalization for HF (48.7\% vs 47.4\%; HR 1.13, 95\% CI 0.81– 1.56), or major adverse cardiovascular events (56.6\% vs 51.3\%; HR 1.22, 95\% CI 0.89–1.66). Longer follow-up of this methodologically high quality trial, which is underway, will cast further light on the potential effects of the MitraClip on important outcomes such as all-cause mortality. Mitra-FR was funded by the French Ministry of Health and Research National Program and Abbott Vascular, and is registered at ClinicalTrials.gov number, NCT01920698.",

year = "2019",

month = feb,

day = "1",

doi = "10.1093/ejcts/ezy396",

language = "English",

volume = "55",

pages = "186--190",

journal = "European Journal of Cardio-thoracic Surgery",

issn = "1010-7940",

publisher = "European Association for Cardio-Thoracic Surgery",

number = "2",

}

TY - JOUR

T1 - 32nd EACTS Annual Meeting clinical trials update

T2 - ART, IMPAG, MITRA-FR and COAPT

AU - Freemantle, Nick

AU - Milojevic, Milan

AU - Lim, Sern

AU - Fremes, Stephen

AU - Pagano, Domenico

N1 - Funding Information: a Institute of Clinical Trials and Methodology, University College London, London, UK b Analytical Support Unit, European Association for Cardio-Thoracic Surgery, Windsor, UK c Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands d Department of Cardiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK e Department of Cardiac Surgery, University of Toronto, Toronto, ON, Canada f Department of Cardiothoracic Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK g Secretary General, European Association for Cardio-Thoracic Surgery, Windsor, UK Funding Information: At 1 year, the regulatory standard composite end point of all-cause death or unplanned hospitalization for HF in the device group was similar to the control group (54.6% vs 51.3%, odds ratio 1.16, 95% CI 0.73–1.84; P = 0.53). There was no difference between the device and the control group in the rate of all-cause death (24.3% vs 22.4%; HR 1.11, 95% CI 0.69–1.77), unplanned hospitalization for HF (48.7% vs 47.4%; HR 1.13, 95% CI 0.81– 1.56), or major adverse cardiovascular events (56.6% vs 51.3%; HR 1.22, 95% CI 0.89–1.66). Longer follow-up of this methodologically high quality trial, which is underway, will cast further light on the potential effects of the MitraClip on important outcomes such as all-cause mortality. Mitra-FR was funded by the French Ministry of Health and Research National Program and Abbott Vascular, and is registered at ClinicalTrials.gov number, NCT01920698.

PY - 2019/2/1

Y1 - 2019/2/1

UR - https://www.scopus.com/pages/publications/85060150210

U2 - 10.1093/ejcts/ezy396

DO - 10.1093/ejcts/ezy396

M3 - Article

C2 - 30388217

AN - SCOPUS:85060150210

SN - 1010-7940

VL - 55

SP - 186

EP - 190

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

IS - 2

ER -